Effects of Treatment Discontinuation in Clinical Psychopharmacology
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acute withdrawal sometimes transitions into a protracted withdrawal syndrome (PWS), which lasts much longer, from months to years.19,20,22”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [22]
In the citing paper
“Across psychotropics, acute withdrawal may last 1–8 weeks after complete discontinuation of the drug.”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [22]
In the citing paper
“In this respect, antidepressants do not differ from other dependence-forming central nervous system (CNS) drugs like benzodiazepines, opioids, gabapentinoids, or psychostimulants.3,19–22”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [22]
In the citing paper
“The evidence supporting this strategy, however, is based mainly on clinical trials where remitted patients were randomized to drug continuation or placebo, without any differentiation between withdrawal and relapse.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [65]
In the citing paper
“we have no way to know how many of the relapses were actually withdrawal and post-withdrawal syndromes in the group that underwent drug tapering and discontinuation.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [65]
Citations
Cites
Cohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Viguera, A. C., Whitfield, T., Baldessarini, R. J., Newport, D. J., Stowe, Z., Reminick, A., Zurick, A., & Cohen, L. S. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06101639 · Cited by 599
Self-citationExploring comorbidity within mental disorders among a Danish national population
Plana-Ripoll, O., Pedersen, C. B., Holtz, Y., Benros, M. E., Dalsgaard, S., de Jonge, P., Fan, C. C., Degenhardt, L., Ganna, A., Greve, A. N., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3658 · Cited by 584
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Viguera, A. C., Nonacs, R., Cohen, L. S., Tondo, L., Murray, A., & Baldessarini, R. J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.179 · Cited by 488
Self-citationTarsy, D., & Baldessarini, R. J. (1974) · Neuropharmacology · doi:10.1016/0028-3908(74)90084-7 · Cited by 446
Self-citationFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder
Suppes, T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360046007 · Cited by 392
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Self-citationClinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors
van Harten, J. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324030-00003 · Cited by 311
Research works printed but not linked: 1
- 10.1177/0269881107081550 · doi:10.1177/0269881107081550 · Paper page
Cited by
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Clinical use of lithium salts: guide for users and prescribers
for the International Group for Studies of Lithium (IGSLi), Tondo, L., Alda, M., Bauer, M., Bergink, V., Grof, P., Hajek, T., Lewitka, U., Licht, R. W., Manchia, M., et al. (2019) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0151-2 · Cited by 204
Self-citationGuidi, J., & Fava, G. A. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3650 · Cited by 155
Lithium Treatment Over the Lifespan in Bipolar Disorders
Volkmann, C., Bschor, T., & Köhler, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00377 · Cited by 145
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Prodromal Symptoms in Depression: A Systematic Review
Benasi, G., Fava, G. A., & Guidi, J. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517953 · Cited by 73
Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
(2022) · doi:10.1192/bja.2021.62 · Cited by 73
Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs
Fava, G. A., & Cosci, F. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19com12794 · Cited by 69
Breedvelt, J. J. F., Warren, F. C., Segal, Z., Kuyken, W., & Bockting, C. L. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0823 · Cited by 68
Nabi, Z., Stansfeld, J. L., Plöderl, M., Wood, L., & Moncrieff, J. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602200049x · Cited by 79
“which participants were taking lithium prior to randomisation was that all psychoactive drugs produce withdrawal syndromes, which may heighten suicide risk (Baldessarini and Tondo, 2019; Cohen and Recalt, 2019).”
BackgroundKathmann, N., Jacobi, T., Elsner, B., & Reuter, B. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000520454 · Cited by 58
Wang, J., & Cosci, F. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000516031 · Cited by 47
The emerging role of euthymia in psychotherapy research and practice
Guidi, J., & Fava, G. A. (2020) · Clinical Psychology Review · doi:10.1016/j.cpr.2020.101941 · Cited by 40
Schiele, M. A., Thiel, C., Kollert, L., Fürst, L., Putschin, L., Kehle, R., Hauke, W., Mahr, M., Reinhold, E., Gottschalk, M. G., et al. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000509910 · Cited by 37
Selective serotonin reuptake inhibitor ‘discontinuation syndrome’ or withdrawal
Massabki, I., & Abi-Jaoude, E. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.269 · Cited by 33
Using Staged Care to Provide “Right Care First Time” to People With Common Affective Disorders
Sawrikar, V., Stewart, E. M., LaMonica, H. M., Iorfino, F., Davenport, T. A., Cross, S. P. M., Scott, E. M., Naismith, S. L., Mowszowski, L., Guastella, A. J., et al. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000145 · Cited by 31
Discontinuing psychotropic drug treatment
Tondo, L., & Baldessarini, R. J. (2020) · BJPsych Open · doi:10.1192/bjo.2020.6 · Cited by 27
Self-citationHow to reduce and stop psychiatric medication
Horowitz, M. A., & Taylor, D. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.001 · Cited by 26
Davies, J., Cooper, R. E., Moncrieff, J., Montagu, L., Rae, T. C., & Parhi, M. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2021.107143 · Cited by 30
Cosci, F., Mansueto, G., & Fava, G. A. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1779308 · Cited by 29
Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations
Cosci, F., Guidi, J., Mansueto, G., & Fava, G. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1804870 · Cited by 31
Hengartner, M. P., & Plöderl, M. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032051 · Cited by 23
Conceptual and Clinical Innovations of Well-being Therapy
Guidi, J., & Fava, G. A. (2021) · International Journal of Cognitive Therapy · doi:10.1007/s41811-021-00101-1 · Cited by 30
Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Schifano, F. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507897 · Cited by 18
Risk factors for early recurrence after discontinuing lithium in bipolar disorder
Baldessarini, R. J., Pinna, M., Contu, M., Vázquez, G. H., & Tondo, L. (2022) · Bipolar Disorders · doi:10.1111/bdi.13206 · Cited by 21
Self-citationCosci, F., Romanazzo, S., Mansueto, G., Rontani, P., Levitan, M. N., Halkjœr-Lassen, R. D., Quagliato, L. A., Nakamura, T., Uematsu, K., Nardi, A. E., et al. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001491 · Cited by 16
Eserian, J. K., Blanco, V. P., Mercuri, L. P., Matos, J. D. R., & Galduróz, J. C. F. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115537 · Cited by 15
Freeman, M. P., Fava, M., Dirks, B., Jha, M. K., Papakostas, G. I., Shelton, R. C., Thase, M. E., Trivedi, M. H., Liu, K., & Stankovic, S. (2020) · Depression and Anxiety · doi:10.1002/da.23017 · Cited by 14
“…Weinstein, & Wagoner, 2005; Francois, Levin, Kutscher, & Asemota, 2017; Sansone & Sansone, 2012), which impacts the response to treatment for MDD (Baldessarini & Tondo, 2019), and is associated with impaired quality of life and increased rates of depression relapse (Ishak et al., 2013; Nurnberg,…”
BackgroundInterventions to help patients withdraw from depression drugs: A systematic review
Gøtzsche, P. C., & Demasi, M. (2024) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230011 · Cited by 16
“Withdrawal symptoms can occur with all psychoactive drugs after prolonged exposure [1,2].”
Horizumi, Y., Tanada, R., Kurosawa, Y., Takatsuka, M., Tsuchida, T., & Goto, S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00702 · Cited by 9
Erwartungseffekte beim Absetzen von Antidepressiva: Implikationen für die Praxis
Nestoriuc, Y. (2022) · Psychotherapeut · doi:10.1007/s00278-022-00587-w · Cited by 10
Cohen, D., & Recalt, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320964097 · Cited by 15
Hamlet’s augury: how to manage discontinuation of mood stabilizers in bipolar disorder
Qureshi, M. M., & Young, A. H. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211000612 · Cited by 13
Peixoto, D. O., Bittencourt, R. R., Gasparotto, J., Kessler, F. G. C., Brum, P. O., Somensi, N., Girardi, C. S., da Silva, L. D. S., Outeiro, T. F., Moreira, J. C. F., et al. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15956 · Cited by 7
“To avoid any possible adverse effects of treatment discontinuation (Baldessarini & Tondo, 2019 ), we opted to reduce the amount of FPS-ZM1 given in the last 2 days of intranasal treatment.”
Moigne, A. L., D, M. F. M., Csernansky, J. G., Newcomer, J. W., & Graham, J. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001319 · Cited by 4
Fava, G. A. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001468 · Cited by 4
Moncrieff, J., Jakobsen, J. C., & Bachmann, M. O. (2021) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2021-111743 · Cited by 4
Kim, J., Stewart, R. J., Kang, H., Kim, J., Lee, J., Ms, J., Lee, J.-Y., Kim, S., & Shin, I. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.06.015 · Cited by 5
Lithium heute — ein Update seiner Wirksamkeit und Risiken
Müller-Oerlinghausen, B. (2019) · NeuroTransmitter · doi:10.1007/s15016-019-6601-3 · Cited by 3
Wang, L., Liu, Y., & Zhao, S. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004350 · Cited by 2
Drug tapering in animal research: current practices and challenges
Zhang, Y., Chen, M., Jiang, T., Fu, Q., Ma, R., Nie, L., You, Y., Gao, S., & Rong, P. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1544784 · Cited by 1
Antidepressant Use and Withdrawal
Cohen, D., Strassle, C. L., & Badre, N. (2025) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2025.10.002 · Cited by 3
Eserian, J. K., de Oliveira, F. F., Mercuri, L. P., Matos, J. D. R., & Galduróz, J. C. F. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10663 · Cited by 1
Pharmacological class interventions for benzodiazepine withdrawal discontinuation: a meta-analysisPreprint
Fluyau, D., Revadigar, N., Mitra, P., & Pierre, C. G. (2020) · medRxiv · doi:10.1101/2020.07.07.20148403 · Cited by 1
He, B., Mao, Y., Hong, C., & Geng, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.24.707855 · Cited by 1
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Comprendre la physiopathologie des syndromes de sevrage
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00004-2
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00007-8
Sgarbossa, C., Meyyappan, A. C., Forth, E., Bromley, H., & Milev, R. V. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1663719
“Baldessarini and Tondo (2019) reported that the immediate discontinuation of antidepressant medication corresponded to an average relapse time of 3 months post-discontinuation of treatment.”
InfluentialGetnet, M., Gashaw, F., Salelew, E., Fanta, B., & Kelebie, M. A. (2026) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-026-03062-y
Moncrieff, J., Long, M., Priebe, S., Akther-Robertson, J., Barnes, T. R. E., Bray, G., Cooper, R. E., Crellin, N. E., Darton, K., Freemantle, N., et al. (2026) · Programme Grants for Applied Research · doi:10.3310/gjjm0506
Metadata
- Authors
- Baldessarini, R. J., & Tondo, L.
- Affiliations
- Harvard University (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2019
- Volume
- 88
- Issue
- 2
- Pages
- 65-70
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2927696747
- Semantic Scholar
- 8758c4235f4af9cfcbd41efb71bb6da771e7dce6
- Cited by
- 52
- References
- 41
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 13 · 2020: 16 · 2019: 3
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- treatment discontinuation, psychopharmacology, antidepressants, relapse
- MeSH terms
- Mental Disorders, Humans, Psychopharmacology, Psychotropic Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.